Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical…


Previous articleIncannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement
Next articleCOMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa